MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 524405 | Name: BAY-751098

Description:

WARNING: This product is for research use only, not for human or veterinary use.

BAY-751098, also known as regorafenib metabolite M4, is a demethylated derivative of Regorafenib. Regorafenib, also known as BAY 73-4506; binds to and inhibits vascular endothelial growth factor receptors (VEGFRs) 2 and 3, and Ret, Kit, PDGFR and Raf kinases, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation. Regorafenib demonstrated to increase the overall survival of patients with metastatic colorectal cancer.

Chemical Structure

BAY-751098
BAY-751098
CAS#1343498-72-5

Theoretical Analysis

MedKoo Cat#: 524405

Name: BAY-751098

CAS#: 1343498-72-5

Chemical Formula: C20H13ClF4N4O3

Exact Mass: 468.0612

Molecular Weight: 468.79

Elemental Analysis: Chemical Formula: C20H13ClF4N4O3 Exact Mass: 468.06123 Molecular Weight: 468.78883 Elemental Analysis: C, 51.24; H, 2.80; Cl, 7.56; F, 16.21; N, 11.95; O, 10.24

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
BAY-751098; BAY 751098; BAY751098; Regorafenib metabolite;
IUPAC/Chemical Name
4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)picolinamide
InChi Key
UJAPQTJRMGFPQS-UHFFFAOYSA-N
InChi Code
InChI=1S/C20H13ClF4N4O3/c21-14-3-1-10(7-13(14)20(23,24)25)28-19(31)29-16-4-2-11(8-15(16)22)32-12-5-6-27-17(9-12)18(26)30/h1-9H,(H2,26,30)(H2,28,29,31)
SMILES Code
c1cc(c(cc1NC(=O)Nc2ccc(cc2F)Oc3ccnc(c3)C(=O)N)C(F)(F)F)Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 468.79 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Victorino APOS, Meton F, Mardegan L, Festa J, Piranda DN, Araujo KB. Trifluridine/tipiracil (FTD/TPI) and regorafenib in older patients with metastatic colorectal cancer. J Geriatr Oncol. 2023 May;14(4):101477. doi: 10.1016/j.jgo.2023.101477. Epub 2023 Mar 27. PMID: 36990929. 2: Khachatryan V, Muazzam A, Hamal C, Velugoti LSDR, Tabowei G, Gaddipati GN, Mukhtar M, Alzubaidee MJ, Dwarampudi RS, Mathew S, Bichenapally S, Mohammed L. The Role of Regorafenib in the Management of Advanced Gastrointestinal Stromal Tumors: A Systematic Review. Cureus. 2022 Sep 1;14(9):e28665. doi: 10.7759/cureus.28665. PMID: 36199644; PMCID: PMC9526434. 3: Blay JY, Duffaud F, George S, Maki RG, Penel N. Regorafenib for the Treatment of Sarcoma. Curr Treat Options Oncol. 2022 Nov;23(11):1477-1502. doi: 10.1007/s11864-022-00990-0. Epub 2022 Sep 30. PMID: 36178573. 4: Liu J, Tao H, Yuan T, Li J, Li J, Liang H, Huang Z, Zhang E. Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy. Front Immunol. 2022 Sep 2;13:992611. doi: 10.3389/fimmu.2022.992611. PMID: 36119072; PMCID: PMC9479218. 5: Akin Telli T, Bregni G, Vanhooren M, Saude Conde R, Hendlisz A, Sclafani F. Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer. Cancer Treat Rev. 2022 Nov;110:102460. doi: 10.1016/j.ctrv.2022.102460. Epub 2022 Aug 27. PMID: 36058142. 6: De Felice M, De Marinis P, Martin G, Bruscella S, De Bellis A, Poliero L, Turitto G. Dramatic response to regorafenib in early glioblastoma progression: case report and review of the literature. Eur Rev Med Pharmacol Sci. 2022 Jul;26(14):5008-5013. doi: 10.26355/eurrev_202207_29287. PMID: 35916797. 7: Yin Q, Guo N, Zhou X, Xu H, Lei S, Fu P, Zhong H. Regorafenib-induced renal- limited thrombotic microangiopathy: a case report and review of literatures. BMC Nephrol. 2022 Mar 19;23(1):112. doi: 10.1186/s12882-021-02656-9. PMID: 35305559; PMCID: PMC8933930. 8: Xu X, Yu Y, Liu M, Liang L, Liu T. Efficacy and safety of regorafenib and fruquintinib as third-line treatment for colorectal cancer: a narrative review. Transl Cancer Res. 2022 Jan;11(1):276-287. doi: 10.21037/tcr-20-3539. PMID: 35261903; PMCID: PMC8841594. 9: Shiri P, Ramezanpour S, Amani AM, Dehaen W. A patent review on efficient strategies for the total synthesis of pazopanib, regorafenib and lenvatinib as novel anti-angiogenesis receptor tyrosine kinase inhibitors for cancer therapy. Mol Divers. 2022 Oct;26(5):2981-3002. doi: 10.1007/s11030-022-10406-8. Epub 2022 Mar 2. PMID: 35235141. 10: Gaudino S, Marziali G, Giordano C, Gigli R, Varcasia G, Magnani F, Chiesa S, Balducci M, Costantini AM, Della Pepa GM, Olivi A, Russo R, Colosimo C. Regorafenib in Glioblastoma Recurrence: How to Deal With MR Imaging Treatments Changes. Front Radiol. 2022 Feb 25;1:790456. doi: 10.3389/fradi.2021.790456. PMID: 37492166; PMCID: PMC10365006. 11: Zhang Y, Zhang F, Zhao L, Fu X, Shang Y, Gao Q. Long-term survival of a patient with microsatellite-stable refractory colorectal cancer with regorafenib and PD-1 inhibitor sintilimab: a case report and review of literature. BMC Gastroenterol. 2021 Oct 23;21(1):399. doi: 10.1186/s12876-021-01950-y. PMID: 34688262; PMCID: PMC8542310. 12: Ouchi R, Okada K, Usui K, Kurata N, Suzuki S, Nagao M, Watanabe Y, Koyama K. Intestinal Perforation in a Patient with Colon Cancer during Treatment with Regorafenib: A Case Report and Review of the Literature. Tohoku J Exp Med. 2021 Jul;254(3):207-211. doi: 10.1620/tjem.254.207. PMID: 34321384. 13: Granito A, Forgione A, Marinelli S, Renzulli M, Ielasi L, Sansone V, Benevento F, Piscaglia F, Tovoli F. Experience with regorafenib in the treatment of hepatocellular carcinoma. Therap Adv Gastroenterol. 2021 May 28;14:17562848211016959. doi: 10.1177/17562848211016959. PMID: 34104211; PMCID: PMC8165525. 14: Granito A, Marinelli S, Forgione A, Renzulli M, Benevento F, Piscaglia F, Tovoli F. Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC. J Hepatocell Carcinoma. 2021 May 26;8:477-492. doi: 10.2147/JHC.S251729. PMID: 34079777; PMCID: PMC8165211. 15: Papadimitriou M, Papadimitriou CA. Antiangiogenic Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: Focusing on Regorafenib. Anticancer Res. 2021 Feb;41(2):567-582. doi: 10.21873/anticanres.14809. PMID: 33517262. 16: Sahin IH, Tan E, Kim R. Regorafenib, an investigational agent for the treatment of cholangiocarcinoma. Expert Opin Investig Drugs. 2021 Apr;30(4):333-341. doi: 10.1080/13543784.2021.1867537. Epub 2020 Dec 30. PMID: 33378249. 17: Mohammadi M, Gelderblom H. Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib. Expert Opin Investig Drugs. 2021 Feb;30(2):143-152. doi: 10.1080/13543784.2021.1857363. Epub 2020 Dec 3. PMID: 33252274. 18: Loupakis F, Antonuzzo L, Bachet JB, Kuan FC, Macarulla T, Pietrantonio F, Xu RH, Taniguchi H, Winder T, Yuki S, Zeng S, Bekaii-Saab T. Practical considerations in the use of regorafenib in metastatic colorectal cancer. Ther Adv Med Oncol. 2020 Oct 31;12:1758835920956862. doi: 10.1177/1758835920956862. PMID: 33193826; PMCID: PMC7607787. 19: Yoshino T. Current and Future Research Into the Mechanism of Action of Regorafenib. Clin Adv Hematol Oncol. 2019 Aug;17 Suppl 12(8):14-16. PMID: 32720934. 20: Prager G. Implications of the Mechanism of Action of Regorafenib for Clinical Practice. Clin Adv Hematol Oncol. 2019 Aug;17 Suppl 12(8):5-13. PMID: 32720933.

View History

Carbofuran-d3

Carbofuran-d3

Featured